#United States #San Diego #WATS3D #CDx Diagnostics #Barrett's Esophagus

CDx Diagnostics Showcases Innovative WATS3D Progress

CDx Diagnostics is set to present groundbreaking clinical findings concerning the WATS3D diagnostic test at the forthcoming Digestive Disease Week (DDW) 2025 event in San Diego. This highly anticipated presentation will highlight the test's efficacy in detecting Barrett's esophagus and related conditions, an advancement that promises to enhance early detection and monitoring of esophageal diseases.

WATS3D has emerged as a vital tool for gastroenterologists, demonstrating significant superiority over traditional forceps biopsy methods. Conventional biopsies often miss nearly 50% of indisputable cases. In contrast, WATS3D captures a broader sample area of the esophageal mucosa and employs advanced three-dimensional imaging technologies to analyze the collected cells. This technique not only improves diagnostic accuracy but also offers physicians critical insights into the progression of Barrett’s esophagus, putting them in a better position to prevent the development of esophageal cancer.

The details of the WATS3D’s impressive capabilities will be shared during a podium presentation titled "Progression Rates of Barrett's Esophagus and Dysplasia Detected by WATS3D Are Similar to Those Diagnosed by Forceps Biopsies." This presentation, led by Dr. Nicholas J. Shaheen, will include collaborative research conducted alongside Dr. Michael Smith, Dr. Vivek Kaul, Mendel Singer Ph.D., and Dr. Robert Odze. The findings from this research confirm the reliability of WATS3D for early detection and emphasize its importance in patient care management.

Furthermore, the conference will feature a related poster presentation titled "MUC2 Immunostaining Predicts Neoplastic Progression as Accurately as the Presence of Goblet Cells in Columnar-Lined Esophagus: A WATS3D Study of 3,553 Patients." These results shed light on the biological significance of lesions detected by WATS3D and their associated risks of progressing to cancer, thereby reinforcing the test’s integral role in clinical settings.

Dr. Shaheen expressed enthusiasm regarding the opportunity to present these insights at DDW. He remarked, "The findings validate WATS3D's role in early detection. We are excited to share these results at DDW and discuss their impact on patient care." Meanwhile, Dr. Odze emphasized how these studies advance understanding of Barrett's esophagus and the potential for early intervention.

The data to be presented at DDW, scheduled from May 3-6, will provide invaluable insights into the evolving landscape of Barrett's esophagus detection, surveillance, and risk assessment strategies. These advancements not only empower healthcare providers with innovative diagnostic tools but also aim to influence clinical practices significantly in the fight against esophageal cancer.

As CDx Diagnostics continues its mission to "Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time," the WATS3D platform has already analyzed over 400,000 cases. This data emphasizes its capability to identify those at risk, reduce time to treatment, and improve clinical outcomes by detecting conditions that traditional biopsy methods might miss.

For further information on CDx Diagnostics and WATS3D, please visit cdxdiagnostics.com or reach out via contact email provided by the company.